Table 2.
Outcome measures of the study cohort.
| Parameter | Baseline | p value | 6 to 8 weeks follow up | p value | 6 months follow up | p value |
|---|---|---|---|---|---|---|
| (6 to 8 weeks compared to baseline) | (6 months compared to 6 to 8 weeks) | (6 months compared to baseline) | ||||
| NYHA > II (%) | 72.8 | <0.001 | 12.4 | 0.02 | 9.6 | <0.001 |
| BNP (pg/ml; mean ± SD) | 841 ± 1,637 | <0.001 | 374 ± 576 | 0.06 | 287 ± 354 | <0.001 |
| SMWD (meters; mean ± SD) | 213 ± 159 | <0.001 | 288 ± 132 | 0.36 | 299 ± 118 | <0.001 |
| LVEF (%; mean ± SD) | 58 ± 15 | <0.001 | 62 ± 13 | 1 | 63 ± 12 | <0.001 |
| Impaired RV-function (%) | 16 | <0.001 | 3 | 0 | 6 | 0 |
| PAPsys (mmHg; mean ± SD) | 41 ± 13 | <0.001 | 35 ± 12 | 0.56 | 35 ± 12 | <0.001 |
| MR ≥ II (%) | 39 | 0 | 27 | 0.17 | 28 | 0.04 |
| TR ≥ II (%) | 32 | 0.26 | 35 | 0.62 | 34 | 0.27 |
| CFS (points; mean ± SD) | 4.0 ± 1.1 | <0.001 | 3.5 ± 1.3 | 0.7 | 3.5 ± 1.1 | 0.45 |
| VAS – self - rated health (points; mean ± SD) | 57 ± 18 | <0.001 | 63 ± 18 | 0.45 | 64 ± 18 | 0.7 |
NYHA, New York Heart Association; BNP, Brain natriuretic peptide; SMWD, 6-min walk distance; LVEF, Left ventricular ejection fraction; RV function, right ventricular function; PAPsys, Systolic pulmonary artery pressure; MR, Mitral regurgitation; TR, Tricuspid regurgitation; CFS, Clinical frailty scale; VAS, Visual analogue scale.